BioLight Announces Distribution Agreement for IOPtiMate™ Systems in China

BioLight Life Sciences Investments Ltd. (OTC: BLGTY, TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announced today that its IOPtima subsidiary has signed an exclusive distribution agreement for the sale and marketing of the IOPtiMate[TM]system in China, one of the world s largest glaucoma markets. As part of the agreement, IOPtima received a commitment that at least 100 systems will be purchased during the initial term of the agreement. The IOPtiMate™ system is based on CO2 laser technology that enablesthe performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, thus allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives. The Chinese partner is a well-known distributor that represents leading global brands in the diagnosis and treatment of ophthalmic diseases. Among its
http://bit.ly/1nAJjK2